Francis Crick, UCL and AZ identify why treatment fails for NSCLC patients
NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients
Read Moreby Jen Brogan | Jun 14, 2024 | News | 0
NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients
Read Moreby John Pinching | Jun 5, 2023 | News | 0
Company’s phase 3 study showed treatment with Tagrisso reduced risk of death by over half
Read Moreby Selina McKee | May 7, 2021 | News | 0
Decision brings the innovative treatment to early-stage lung cancer patients, helping to address unmet need in this setting
Read Moreby Lucy Parsons | Apr 27, 2021 | News | 0
Therapy wins a positive CHMP opinion for the adjuvant treatment of early-stage EGFR-mutated NSCLC
Read Moreby Lucy Parsons | Dec 21, 2020 | News | 0
EGFR-TKI approved in the US for early non-small cell lung cancer
Read Moreby Lucy Parsons | Oct 20, 2020 | News | 0
Agency will review drug for the treatment of early-stage EGFR-mutated lung cancer
Read Moreby Selina McKee | Sep 14, 2020 | News | 0
The Institute has endorsed the drug for first-line treatment of adults with locally-advanced or EGFR mutation-positive NSCLC
Read Moreby Selina McKee | May 29, 2020 | News | 0
The Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent the the risk of disease recurrence or death by around 80%
Read Moreby Anna Smith | Jan 24, 2020 | News | 0
Unfortunately, the drug is not considered eligible for inclusion in the Cancer Drugs Fund either.
Read Moreby Anna Smith | Aug 9, 2019 | News | 0
The trial previously met its primary endpoint in July 2017, showing a statistically-significant and clinically-meaningful improvement in progression-free survival.
Read Moreby Anna Smith | Jul 8, 2019 | News | 0
The committee didn’t OK the drug as the cost effectiveness estimates were above what NICE normally considers to be an acceptable use of NHS resources.
Read Moreby Anna Smith | Apr 3, 2019 | News | 0
The news was announced at the American Association for Cancer Research (AACR) annual meeting.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
